News | August 19, 2024
Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
KIMS already have a multi-specialty hospital and gastro unit at Vizag
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Subscribe To Our Newsletter & Stay Updated
